1. Polyprenols mitigate cognitive dysfunction and neuropathology in the APP/PS1 mouse
- Author
-
Ling He, Nan Hua, Yu-Hui Hu, Xu-Xu Zhuang, Guang-Yao Zheng, Xuan Zang, and Yi Sun
- Subjects
Male ,0301 basic medicine ,Genetically modified mouse ,Mice, Transgenic ,Neuropathology ,Pharmacology ,Neuroprotection ,Mice ,03 medical and health sciences ,0302 clinical medicine ,mental disorders ,Animals ,Humans ,Medicine ,Cognitive Dysfunction ,Senile plaques ,business.industry ,Cognition ,Disease Models, Animal ,Phosphotransferases (Alcohol Group Acceptor) ,030104 developmental biology ,Behavioral test ,Apoptosis ,Immunohistochemistry ,Cognition Disorders ,business ,030217 neurology & neurosurgery - Abstract
Alzheimer's disease (AD) is a very common neurodegenerative disorder in the elderly and brings considerable financial and social problems worldwide. In this study, polyprenols were firstly evaluated the effects on the cognitive deficits and neuropathology in APP/PS1 mice model of AD. At 3 months old, the APP/PS1 mice were divided into model group; polyprenols low, middle, and high dosage group; and positive drug group. Age-matched wild-type mice were chosen in control group. The administration by oral gavage lasted 6 months. Polyprenols treatment significantly improved cognitive impairment of double transgenic mice compared with vehicle control treatment in behavioral tests. In addition, immunohistochemistry and enzyme-linked immunosorbent assay showed that there were significantly reductions in neuritic plaques and the level of hyperphosphorylated tau in brain of polyprenols-treated mice. Furthermore, we found that polyprenols treatment reduced the apoptotic cells in brain sections of 9-month-old APP/PS1 mice. These results reveal that polyprenols exert neuroprotective effects in APP/PS1 mice and could represent an effective treatment for AD.
- Published
- 2018